Other considerations of continuous therapy with an oral BTK inhibitor include the risk of skin cancer; the need for patients to see their oncologists or family physician at least every three months for vital sign measurements; the importance of interrupting BTK inhibitor therapy when surgery is planned; and the necessity of education for both patients and other health care professionals. This evidence concerns the gene BTK and skin neoplasm.